AlphaCentric Advisors’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
AlphaCentric Advisors's VRDN Position: Q3 2026 in Review
AlphaCentric Advisors opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 10,480 shares worth $216K. The stake represents 0.19% of the portfolio and ranks #143 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in VRDN as recently as Q3 2024.
AlphaCentric Advisors first reported a position in VRDN in Q3 2022 and has held it in 9 quarters since. The position peaked at $1.23M in Q3 2023. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- AlphaCentric Advisors held 10,480 shares of Viridian Therapeutics worth $216K as of Q3 2026.
- Viridian Therapeutics was a new AlphaCentric Advisors position in Q3 2026.
- Viridian Therapeutics made up 0.19% of AlphaCentric Advisors's portfolio in Q3 2026, its #143 holding.
- AlphaCentric Advisors first reported a position in Viridian Therapeutics in Q3 2022 and has held it in 9 quarters since.
- AlphaCentric Advisors's Viridian Therapeutics position peaked at $1.23M in Q3 2023.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.